| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In ectopic cell lines, quinaglidide hydrochloride (100 nM; 48 hours) decreases the expression of non-ergot dopamine receptor 2 (DRD2) mRNA [2]. Endocrine mesenchymal stromal cells' (E-MSC) ability to invade is inhibited by quinagolide hydrochloride (100 nM; 48 hours) [2]. Endothelial differentiation of E-MSCs is greatly reduced by quinagolide hydrochronide (100 nM; 24 hours) [2].
|
|---|---|
| ln Vivo |
Quinagolide hydrochloride (0.03-0.6 mg/kg; subcutaneous injection, once daily for 2 months) can effectively inhibit tumor growth in the body [1].
|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: In situ and ectopic E-MSCs Tested Concentrations: 100 nM Incubation Duration: 24 hrs (hours) Experimental Results: Total AKT levels diminished in ectopic E-MSCs, AKT in situ and ectopic cell lines Phosphorylation is Dramatically diminished. |
| Animal Protocol |
Animal/Disease Models: Female Wistar-Furth rats bearing SMtTW tumors [1]
Doses: 0.03-0.6 mg/kg Route of Administration: subcutaneous injection; 0.03-0.6 mg/kg, one time/day for 2 months Experimental Results: vs. Plasma PRL levels in all animals tended to normalize and tumor size diminished compared with the control group at a dose of 0.3 mg/kg. The dose of 0.3 mg/kg demonstrated the greatest inhibitory effect on PRL secretion and tumor growth. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation Quinagolide is not approved for marketing in the US by the US Food and Drug Administration. It is selective dopamine D2 receptor that reduces serum prolactin. Quinagolide is usually not used during breastfeeding because it suppresses lactation. No published information was found on the use of quinagolide in nursing mothers. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk A small preliminary study compared quinagolide (CV 205-502) to bromocriptine for 21 days starting in the first day postpartum in mothers who did not wish to breastfeed. Serum prolactin normalized more rapidly with bromocriptine and more women had breast symptoms with quinagolide. Efficacy in suppressing lactation was similar between the groups.[1] |
| References |
|
| Additional Infomation |
See also: Quinagolide hydrochloride (annotation moved to).
|
| Molecular Formula |
C20H33N3O3S.HCL
|
|---|---|
| Molecular Weight |
432.02026
|
| Exact Mass |
431.201
|
| CAS # |
94424-50-7
|
| Related CAS # |
94424-50-7 (HCl);87056-78-8;
|
| PubChem CID |
3086400
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
539.1ºC at 760 mmHg
|
| Flash Point |
279.8ºC
|
| LogP |
4.347
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
28
|
| Complexity |
576
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CCCN1C[C@H](C[C@H]2[C@H]1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC.Cl
|
| InChi Key |
DVLKVIJLALMCBQ-MSSRUXLCSA-N
|
| InChi Code |
InChI=1S/C20H33N3O3S.ClH/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24;/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3;1H/t16-,17+,19-;/m1./s1
|
| Chemical Name |
(3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~3.85 mg/mL (~8.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3147 mL | 11.5735 mL | 23.1471 mL | |
| 5 mM | 0.4629 mL | 2.3147 mL | 4.6294 mL | |
| 10 mM | 0.2315 mL | 1.1574 mL | 2.3147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
